Sandoz Canada is looking to bolster its portfolio of biosimilars after obtaining marketing authorizations for both pegfilgrastim and rituximab.

Despite having biosimilars of insulin glargine and etanercept that are expected to launch in the US and Europe respectively midway through this year, a biosimilar bevacizumab candidate filed in both regions, an in-development Botox rival still being considered and several other biosimilars already on the market around the world, Mylan insists that its biosimilars journey is just beginning.

Mylan and Biocon have launched their Fulphila biosimilar version of pegfilgrastim in Australia, marking the pair’s third local biosimilar launch under their partnership.